A Phase 2 interventional study of Placebo and GSK2330672 in Cholestasis, sponsored by GlaxoSmithKline. Completed at 66 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-04.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will receive either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram [mg], 90 mg or 180 mg taken once daily or 90 mg twice daily). Participants on GSK2330672 will also receive placebo tablets to maintain blinding. The study has a prospectively defined adaptive design that will utilize interim data to further inform and potentially optimize the doses under investigation. Hence, additional dose regimen may be added during study. The total duration of a participant in the study will be up to 45 days of screening and 24 weeks of study including follow-up.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
This study's enrollment of 147 is above the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Browse Liver Cirrhosis, Biliary studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Liver Cirrhosis, Biliary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cholestasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive matching placebo
Drug: Placebo
Participants will receive GSK2330672 and matching placebo to maintain blind
Drug: Placebo · Drug: GSK2330672
Participants will receive GSK2330672 and matching placebo to maintain blind
Drug: Placebo · Drug: GSK2330672
Participants will receive GSK2330672 and matching placebo to maintain blind
Drug: Placebo · Drug: GSK2330672
Participants will receive GSK2330672 and matching placebo to maintain blind
Drug: Placebo · Drug: GSK2330672
Participants will receive GSK2330672 and matching placebo to maintain blind
Drug: Placebo · Drug: GSK2330672
GSK2330672 matching placebo will be supplied as white film-coated tablets.
GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score
Participants were required to score the severity of their itching using a 0-10 numerical rating scale (NRS) where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the average of the scores in the 7 days prior to the Week 4 (Visit 3 \[V3\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was done using Analysis of covariance (ANCOVA) including treatment group and centered Mean Worst Daily Itch score at Baseline.
Time frame: Baseline and Week 16
Mean Change From Baseline at Week 16 in Primary Biliary Cholangitis-40 (PBC-40) Scale
PBC-40 is a disease-specific health-related quality of life (HRQoL) questionnaire for use in PBC participants. It consists of 40 questions arranged in 6 domains with 3 to 11 questions in each domain. Each question is scored from 1 (least impact) to 5 (greatest impact). All questions within a domain are summed to obtain individual domain score. Domains were: Symptoms (7 questions) with score range 7-35, Itch (3 questions) with score range 3-15, Fatigue (11 questions) with score range 11-55, Cognitive (6 questions) with score range 6-30, Emotional (3 questions) with score range 3-15, and Social (10 questions) with score range 10-50. Higher scores for individual domains represent a poor quality of life. Baseline is the assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Serum Alkaline Phosphatase (ALP) Concentrations, in Participants With High Risk of PBC Progression
Criteria for high risk of PBC progression is defined as serum ALP concentrations more than or equal to (\>=)1.67 times upper limit of normal (ULN) range and/or total bilirubin concentrations more than (\>)ULN at Day 1. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
Time frame: Baseline and at Week 16
Number of Participants With Serum ALP Concentrations Less Than (<)1.67 Times ULN and Total Bilirubin Concentrations Less Than or Equal to (<=) ULN at Week 16
Number of participants with ALP \< 1.67 times ULN and total bilirubin \<= ULN at Week 16 is presented. The endpoint was analyzed in Restricted High Risk Population.
Time frame: At Week 16
Mean Change From Baseline at Week 16 in Serum Alanine Aminotransferase (ALT) Among Those With a High Risk of PBC Progression
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Serum Aspartate Aminotransferase (AST) Among Those With a High Risk of PBC Progression
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Serum Gamma Glutamyl Transferase (GGT), Among Those With a High Risk of PBC Progression
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Total Bilirubin Concentration, Among Those With a High Risk of PBC Progression
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Albumin Concentration, Among Those With a High Risk of PBC Progression
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Prothrombin International Normalized Ratio (INR), Among Those With a High Risk of PBC Progression
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Prothrombin Time, Among Those With a High Risk of PBC Progression
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
Time frame: Baseline and at Week 16
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) -Main Study Period
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.
Time frame: Up to 12 weeks
Number of Participants With Non-SAEs and SAEs -Final Study Period
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.
Time frame: Up to 4 weeks
Number of Participants With Non-SAEs and SAEs - Follow-up Period
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.
Time frame: Up to 4 weeks
Number of Participants With Clinical Chemistry Data of Potential Clinical Importance
Blood samples were collected to measure analyze the following parameters: albumin, calcium, Glomerular filtration rate (GFR) from creatinine, glucose, potassium and sodium. Participants were counted in the worst case category that their value changes to (low, within range \[w/in\] or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example \[e.g.\], high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100 percent (%). Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.
Time frame: At Weeks 8, 12, 16 and 20
Number of Participants With Hematology Data of Potential Clinical Importance
Blood samples were collected to analyze the following parameters: hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. Participants were counted in the worst case category that their value changes to (low, w/in or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100%. Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.
Time frame: At Weeks 8, 12, 16 and 20
Number of Participants With Abnormal 12-Lead Electrocardiogram (ECG) Parameters
A 12-lead ECG was recorded with the participant in a semi-supine position. 12-lead ECGs were obtained by using an automated ECG machine. Data for abnormal, not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: At Weeks 8, 12, 16 and 20
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 20
Change From Baseline in Pulse Rate
Pulse rate was measured in a semi-supine position after 5 minutes of rest. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and Week 20
Change From Baseline in Gastrointestinal Symptom Rating Scale (GSRS) Assessment
GSRS is a validated scale used to assess gastrointestinal symptoms experienced by participants over the preceding 5 to 7 days. GSRS was measured for all 5 domains: Average Diarrhea Syndrome Score, Average Indigestion Syndrome Score, Average Constipation Syndrome Score, Average Abdominal Pain Syndrome Score, Average Reflux Syndrome Score. All individual domains are scored on a 7-point Likert scale ranging from 1(not at all) to 7(extremely). Higher score indicate more severe symptoms. The Average Total GSRS score was mean of these 5 domains and ranges from 1 to 7. Higher score indicates worst possible degree of symptoms. The responses summarized at each visit are those given during the week prior to the visit, with exception of Day 1. Baseline is the most recent assessment completed by participant prior to randomization. Change from Baseline was calculated as post-Baseline value minus the Baseline value. Data has been presented for each domain along with the average Total GSRS score.
Time frame: Baseline and Week 20
Number of Participants With Mean Worst Daily Itch Score of <4 at Week 16
Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Number of participants with Mean Worst Daily Itch Score of \<4 at Week 16 is presented.
Time frame: At Week 16
Number of Participants With Improvement of >= 30 Percent (%) in the Mean Worst Daily Itch Score at Week 16 From Baseline
Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.
Time frame: Baseline and At Week 16
Number of Participants With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline
Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.
Time frame: Baseline and At Week 16
Percentage of Responder Days With Worst Daily Itch Score of <4
Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Percentage of responder days with Worst Daily Itch Score of \<4 is presented.
Time frame: Up to Week 16
Percentage of Responder Days With Improvement of >= 30% in the Mean Worst Daily Itch Score at Week 16 From Baseline
Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented..
Time frame: Baseline and at Week 16
Percentage of Responder Days With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline
Percentage of Responder Days with Worst Daily Itch was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.
Time frame: Baseline and at Week 16
Change From Baseline in the Mean Daily Sleep Score at Week 16
Mean Daily Sleep Score is defined as the average of the daily sleep scores provided in the 7 days prior to the relevant visit. Participants sleep quality was recorded in an electronic diary each morning using a 0-10 NRS in which 0: good sleep to 10:worst possible sleep. Higher score indicates worse possible sleep. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
Time frame: Baseline and at Week 16
Change From Baseline in the Mean Daily Fatigue Score at Week 16
Mean Daily Fatigue Score is defined as the average of the daily fatigue scores provided in the 7 days prior to the relevant visit. Participants fatigue level was recorded in an electronic diary each evening using a 0-10 NRS in which 0: no fatigue to 10:worst possible fatigue. Higher score indicates worse possible fatigue. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
Time frame: Baseline and at Week 16
Change From Baseline in the Five-Dimensional (5-D) Itch Scale at Week 16
The 5-D itch scale had been developed as a brief, single page, instrument for the multidimensional quantification of itch that is sensitive to change over time. It has data to support its validity in a population of participants with pruritus and covers five dimensions of itch experienced by participants: duration, degree, direction, disability and distribution. Each domain was scored on a 5-point scale, ranging from 1 (Not present/resolved/never) to 5 (unbearable/getting worse/always), higher scores indicates worst itching. The scores of each of five domains were achieved separately and then summed together to obtain a total 5-D score. A total 5-D scores potentially ranged between 5 (no pruritus) and 25 (most severe pruritus) where higher score indicates worse possible itching. Baseline is assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Serum Total Bile Acid Concentration
Blood samples were collected for evaluating total bile acid concentration as a biomarker of PBC. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and at Week 16
Mean Change From Baseline at Week 16 in Serum 7-alpha Hydroxy-4-cholesten-3-one (C4)
Blood samples were collected for evaluating C4 concentration as a marker of bile acid synthesis. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline and at Week 16
Plasma Concentration of GSK2330672 After Sparse Sampling
Blood samples were collected for measurement of plasma GSK2330672 concentration.
Time frame: At Week 4 (between 1 and 3 hours post-dose) and At Weeks 8, 12 and 16 (between 1 and 3 hours post-dose, and between 5 and 8 hours post-dose)
This study was conducted across 66 centers in 10 countries. The 40 milligrams (mg) twice daily dose group was added and recruitment into the 20 mg twice daily dose group was discontinued following the pre-specified interim analysis.
| Milestone | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Started | 36 | 16 | 23 | 27 | 23 | 22 |
| Completed | 35 | 16 | 19 | 19 | 22 | 17 |
| Not completed | 1 | 0 | 4 | 8 | 1 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Discontinued study treatment and entered follow-up | 0 | 0 | 4 | 8 | 0 | 5 |
| Milestone | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Started | 35 | 16 | 19 | 19 | 21 | 17 |
| Completed | 35 | 16 | 19 | 19 | 21 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Started | 35 | 16 | 23 | 27 | 22 | 22 |
| Completed | 35 | 16 | 22 | 22 | 22 | 21 |
| Not completed | 0 | 0 | 1 | 5 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 |
Participants were required to score the severity of their itching using a 0-10 numerical rating scale (NRS) where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the average of the scores in the 7 days prior to the Week 4 (Visit 3 \[V3\]). Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was done using Analysis of covariance (ANCOVA) including treatment group and centered Mean Worst Daily Itch score at Baseline.
| Scores on a scale | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch Score | -1.73 (-2.44 to -1.01) | -2.19 (-3.26 to -1.12) | -2.60 (-3.55 to -1.65) | -2.60 (-3.51 to -1.70) | -2.86 (-3.76 to -1.95) | -2.25 (-3.19 to -1.32) |
PBC-40 is a disease-specific health-related quality of life (HRQoL) questionnaire for use in PBC participants. It consists of 40 questions arranged in 6 domains with 3 to 11 questions in each domain. Each question is scored from 1 (least impact) to 5 (greatest impact). All questions within a domain are summed to obtain individual domain score. Domains were: Symptoms (7 questions) with score range 7-35, Itch (3 questions) with score range 3-15, Fatigue (11 questions) with score range 11-55, Cognitive (6 questions) with score range 6-30, Emotional (3 questions) with score range 3-15, and Social (10 questions) with score range 10-50. Higher scores for individual domains represent a poor quality of life. Baseline is the assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
| Scores on a scale | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Symptoms | 0.2 (-1.0 to 1.4) | 0.4 (-1.3 to 2.2) | 0.7 (-0.8 to 2.3) | -0.9 (-2.4 to 0.6) | 0.3 (-1.2 to 1.8) | 0.2 (-1.4 to 1.8) |
| Itch | -2.3 (-3.3 to -1.4) | -1.9 (-3.3 to -0.4) | -2.6 (-3.9 to -1.3) | -2.7 (-3.9 to -1.4) | -3.4 (-4.6 to -2.1) | -2.7 (-4.0 to -1.4) |
| Fatigue | -1.8 (-4.0 to 0.4) | -2.4 (-5.6 to 0.7) | -1.1 (-3.8 to 1.7) | 1.7 (-1.0 to 4.5) | -0.1 (-2.8 to 2.6) | -1.8 (-4.6 to 1.1) |
| Cognitive | -0.3 (-1.7 to 1.1) | -0.3 (-2.4 to 1.8) | -0.9 (-2.7 to 0.9) | -0.1 (-1.9 to 1.6) | 0.1 (-1.6 to 1.9) | -0.1 (-2.0 to 1.7) |
| Emotional | -0.5 (-1.2 to 0.1) | -1.4 (-2.4 to -0.4) | -0.4 (-1.3 to 0.5) | -0.6 (-1.5 to 0.3) | -1.4 (-2.2 to -0.5) | -0.6 (-1.5 to 0.3) |
| Social | -0.8 (-2.3 to 0.8) | -0.5 (-2.7 to 1.8) | 0.4 (-1.5 to 2.4) | -0.6 (-2.5 to 1.3) | -3.1 (-5.1 to -1.2) | -1.0 (-3.0 to 1.0) |
Criteria for high risk of PBC progression is defined as serum ALP concentrations more than or equal to (\>=)1.67 times upper limit of normal (ULN) range and/or total bilirubin concentrations more than (\>)ULN at Day 1. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
| International units per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Serum Alkaline Phosphatase (ALP) Concentrations, in Participants With High Risk of PBC Progression | 49.1 (-29.3 to 127.6) | -57.7 (-179.6 to 64.3) | -38.2 (-117.0 to 40.5) | 49.6 (-49.1 to 148.2) | -29.2 (-136.7 to 78.3) | 19.1 (-97.7 to 136.0) |
Number of participants with ALP \< 1.67 times ULN and total bilirubin \<= ULN at Week 16 is presented. The endpoint was analyzed in Restricted High Risk Population.
| Participants | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Number of Participants With Serum ALP Concentrations Less Than (<)1.67 Times ULN and Total Bilirubin Concentrations Less Than or Equal to (<=) ULN at Week 16 | 0 | 0 | 0 | 0 | 0 | 1 |
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.
| International Units per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Serum Alanine Aminotransferase (ALT) Among Those With a High Risk of PBC Progression | 13.0 (-7.9 to 33.9) | -8.4 (-39.5 to 22.7) | 0.3 (-20.7 to 21.2) | -2.0 (-29.0 to 25.1) | -13.5 (-42.8 to 15.9) | 13.2 (-17.4 to 43.7) |
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including Treatment group and Baseline.
| International Units per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Serum Aspartate Aminotransferase (AST) Among Those With a High Risk of PBC Progression | 13.96 (-4.55 to 32.46) | -6.04 (-34.20 to 22.12) | -10.75 (-28.90 to 7.40) | -8.66 (-32.24 to 14.93) | -17.72 (-42.77 to 7.34) | 8.16 (-18.72 to 35.04) |
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
| International Units per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Serum Gamma Glutamyl Transferase (GGT), Among Those With a High Risk of PBC Progression | 47.5 (-9.9 to 104.8) | -58.5 (-142.5 to 25.5) | -18.0 (-74.9 to 38.9) | 4.6 (-66.5 to 75.8) | -18.4 (-93.6 to 56.8) | -6.7 (-89.1 to 75.8) |
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
| Micromoles per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Total Bilirubin Concentration, Among Those With a High Risk of PBC Progression | 1.258 (-2.068 to 4.583) | -4.841 (-9.693 to 0.011) | -1.079 (-4.345 to 2.187) | -0.975 (-5.150 to 3.201) | -0.234 (-4.914 to 4.446) | 6.494 (1.622 to 11.365) |
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
| Grams per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Albumin Concentration, Among Those With a High Risk of PBC Progression | 0.0 (-1.2 to 1.3) | -0.5 (-2.3 to 1.3) | 0.3 (-1.0 to 1.6) | 0.8 (-0.8 to 2.3) | 0.0 (-1.7 to 1.7) | 0.7 (-1.1 to 2.5) |
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
| Ratio | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Prothrombin International Normalized Ratio (INR), Among Those With a High Risk of PBC Progression | 0.01 (-0.03 to 0.05) | -0.01 (-0.06 to 0.04) | -0.03 (-0.06 to 0.00) | 0.01 (-0.04 to 0.05) | -0.02 (-0.07 to 0.02) | -0.03 (-0.08 to 0.02) |
Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
| Seconds | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Prothrombin Time, Among Those With a High Risk of PBC Progression | -0.10 (-0.40 to 0.20) | 0.05 (-0.33 to 0.44) | -0.21 (-0.47 to 0.05) | 0.02 (-0.33 to 0.37) | -0.18 (-0.51 to 0.15) | -0.17 (-0.55 to 0.22) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.
| Participants | Placebo -Main Study Period | GSK2330672 20 mg QD - Main Study Period | GSK2330672 90 mg QD - Main Study Period | GSK2330672 180 mg QD - Main Study Period | GSK2330672 40 mg BID - Main Study Period | GSK2330672 90 mg BID - Main Study Period |
|---|---|---|---|---|---|---|
| Any non-SAE | 17 | 11 | 19 | 24 | 16 | 18 |
| Any SAE | 0 | 0 | 1 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.
| Participants | Placebo - Final Study Period | GSK2330672 20 mg QD - Final Study Period | GSK2330672 90 mg QD - Final Study Period | GSK2330672 180 mg QD - Final Study Period | GSK2330672 40 mg BID - Final Study Period | GSK2330672 90 mg BID - Final Study Period |
|---|---|---|---|---|---|---|
| Any non-SAE | 2 | 6 | 8 | 2 | 2 | 2 |
| Any SAE | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any untoward event resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persisting disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment is categorized as SAE.
| Participants | Placebo - Follow-up | GSK2330672 20 mg QD - Follow-up | GSK2330672 90 mg QD - Follow-up | GSK2330672 180 mg QD - Follow-up | GSK2330672 40 mg BID - Follow-up | GSK2330672 90 mg BID - Follow-up |
|---|---|---|---|---|---|---|
| Any non-SAE | 0 | 0 | 0 | 0 | 0 | 0 |
| Any SAE | 0 | 1 | 0 | 1 | 0 | 0 |
Blood samples were collected to measure analyze the following parameters: albumin, calcium, Glomerular filtration rate (GFR) from creatinine, glucose, potassium and sodium. Participants were counted in the worst case category that their value changes to (low, within range \[w/in\] or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example \[e.g.\], high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100 percent (%). Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.
| Participants | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Albumin, To Low, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin, To Low, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin, To Low, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin, To Low, Week 20, n=35, 16, 22, 22, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To Low, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To High, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To Low, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To High, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To Low, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To High, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To Low, Week 20, n=35, 16, 22, 22, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, To High, Week 20, n=35, 16, 22, 22, 22, 21 | 1 | 0 | 0 | 0 | 0 | 0 |
| GFR, To Low, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| GFR, To Low, Week 12, n=35, 15, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| GFR, To Low, Week 16, n=35, 16, 21, 22, 21, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| GFR, To Low, Week 20, n=35, 16, 22, 22, 22, 21 | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose ,To Low, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose ,To High, Week 8, n=36, 16, 21, 21, 22, 19 | 1 | 0 | 0 | 0 | 0 | 1 |
| Glucose ,To Low, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose, To High, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose ,To Low, Week 16, n=35, 16, 21, 22, 21,20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose, To High, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose ,To Low, Week 20, n=35, 16, 22, 22, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose, To High, Week 20, n=35, 16, 22, 22, 22, 21 | 1 | 0 | 0 | 0 | 0 | 0 |
| Potassium,To Low, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, To High, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium,To Low, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, To High, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium,To Low, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, To High, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium,To Low, Week 20, n=35, 16, 22, 22, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, To High, Week 20, n=35, 16, 22,22, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To Low, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To High, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To Low, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To High, Week 12, n=35, 16, 21, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To Low, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To High, Week 16, n=35, 16, 21, 22, 21, 20 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sodium, To Low, Week 20, n=35, 16, 22, 22, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium, To High, Week 20, n=35, 16, 22, 22, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected to analyze the following parameters: hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. Participants were counted in the worst case category that their value changes to (low, w/in or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., high to high), or whose value became within range, were recorded in the "To w/in Range or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100%. Only "To Low" and/or "To High" categories with potential clinical importance data have been presented.
| Participants | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Hematocrit, To High, Week 8,n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit, To High, Week 12, n=33, 15, 21, 23, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit, To High, Week 16, n=35, 15, 21, 22, 21, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit, To High, Week 20, n=34, 16, 22, 22, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To High, Week 8,n=36,16, 21, 21, 22,19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To High, Week 12, n=33,15, 21, 23, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To High, Week 16, n=35, 15, 21, 22, 21, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, To High, Week 20, n=34,16, 22, 22, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes, To Low, Week 8, n=36,15, 21, 21, 22,19 | 1 | 0 | 0 | 0 | 1 | 0 |
| Leukocytes,To High, Week 8, n=36,15, 21, 21, 22,19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes, To Low, Week 12, n=33,15, 21, 23, 22, 20 | 1 | 1 | 1 | 0 | 0 | 0 |
| Leukocytes,To High, Week 12, n=33,15,21,23, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes, To Low, Week 16, n=34, 15, 21, 22, 20, 21 | 1 | 0 | 3 | 1 | 1 | 0 |
| Leukocytes,To High, Week 16, n=34, 15, 21, 22, 20, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Leukocytes, To Low, Week 20, n=34,16, 22, 21, 22, 19 | 0 | 1 | 1 | 0 | 0 | 0 |
| Leukocytes, To High, Week 20, n=34,16, 22, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, To Low, Week 8, n=35,15, 21, 21, 22, 19 | 2 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, To Low, Week 12, n=32,15,21,23, 22, 20 | 1 | 0 | 0 | 2 | 0 | 0 |
| Lymphocytes, To Low, Week 16, n=34, 15, 21, 22, 20, 21 | 0 | 0 | 0 | 1 | 0 | 0 |
| Lymphocytes, To Low, Week 20, n=34,16, 22, 21, 22, 19 | 0 | 0 | 1 | 0 | 0 | 0 |
| Neutrophils, To Low, Week 8,n=35,15, 21, 21, 22, 19 | 1 | 1 | 0 | 1 | 1 | 1 |
| Neutrophils, To Low, Week 12, n=32, 15, 21, 23, 22, 20 | 0 | 1 | 0 | 1 | 0 | 1 |
| Neutrophils, To Low, Week 16, n=34, 15, 21, 22, 20, 21 | 1 | 0 | 2 | 0 | 1 | 0 |
| Neutrophils, To Low, Week 20, n=34,16, 22, 21, 22,19 | 0 | 0 | 1 | 0 | 0 | 0 |
| Platelets, To Low, Week 8,n=36,15, 20, 21, 22,19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets, To High, Week 8,n=36,15, 20, 21, 22, 19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets, To Low, Week 12, n=33,14,19, 23, 22, 20 | 0 | 0 | 0 | 0 | 0 | 1 |
| Platelets,To High, Week 12, n=33, 14, 19, 23, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets, To Low, Week 16, n=35, 14, 19, 22, 21, 21 | 1 | 0 | 0 | 0 | 0 | 1 |
| Platelets,To High, Week 16, n=35, 14, 19, 22, 21, 21 | 1 | 0 | 0 | 0 | 0 | 0 |
| Platelets, To Low, Week 20, n=33,16, 21, 21, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets,To High, Week 20, n=33, 16, 21, 21, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
A 12-lead ECG was recorded with the participant in a semi-supine position. 12-lead ECGs were obtained by using an automated ECG machine. Data for abnormal, not clinically significant (NCS) and clinically significant (CS) ECG findings are presented. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Abnormal, NCS, Week 8, n=36, 16, 21, 21, 22,19 | 10 | 2 | 1 | 7 | 8 | 4 |
| Abnormal, CS, Week 8, n=36, 16, 21, 21, 22, 19 | 0 | 0 | 0 | 1 | 0 | 0 |
| Abnormal, NCS, Week 12, n= 35, 16, 20, 23, 22, 21 | 9 | 3 | 3 | 8 | 8 | 4 |
| Abnormal, CS, Week 12, n=35, 16, 20, 23, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal, NCS, Week 16, n= 35, 16, 21, 21, 22 ,21 | 9 | 3 | 2 | 5 | 7 | 4 |
| Abnormal, CS, Week 16, n=35, 16, 21, 21, 22, 21 | 0 | 0 | 0 | 0 | 0 | 0 |
| Abnormal, NCS, Week 20, n=35, 16, 22, 22, 22, 20 | 8 | 3 | 2 | 7 | 8 | 3 |
| Abnormal, CS, Week 20, n=35, 16, 22, 22, 22, 20 | 0 | 0 | 0 | 0 | 0 | 0 |
SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Millimeters of mercury (mmHg) | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| SBP | -3.3 ± 13.33 | -2.1 ± 11.47 | 0.1 ± 12.78 | 0.7 ± 10.42 | -0.3 ± 15.16 | 2.0 ± 15.43 |
| DBP | -1.3 ± 8.99 | 0.3 ± 7.75 | -0.3 ± 9.16 | -0.7 ± 5.51 | 2.5 ± 8.64 | 2.3 ± 7.23 |
Pulse rate was measured in a semi-supine position after 5 minutes of rest. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Beats per minute | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in Pulse Rate | 1.5 ± 7.19 | -2.6 ± 10.35 | 1.2 ± 10.91 | -0.2 ± 7.93 | 3.4 ± 8.92 | 0.5 ± 8.03 |
GSRS is a validated scale used to assess gastrointestinal symptoms experienced by participants over the preceding 5 to 7 days. GSRS was measured for all 5 domains: Average Diarrhea Syndrome Score, Average Indigestion Syndrome Score, Average Constipation Syndrome Score, Average Abdominal Pain Syndrome Score, Average Reflux Syndrome Score. All individual domains are scored on a 7-point Likert scale ranging from 1(not at all) to 7(extremely). Higher score indicate more severe symptoms. The Average Total GSRS score was mean of these 5 domains and ranges from 1 to 7. Higher score indicates worst possible degree of symptoms. The responses summarized at each visit are those given during the week prior to the visit, with exception of Day 1. Baseline is the most recent assessment completed by participant prior to randomization. Change from Baseline was calculated as post-Baseline value minus the Baseline value. Data has been presented for each domain along with the average Total GSRS score.
| Scores on a scale | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Average Diarrhea Syndrome Score | 0.22 ± 1.343 | 0.15 ± 1.587 | 0.23 ± 1.180 | -0.13 ± 0.637 | -0.23 ± 1.729 | 0.22 ± 1.565 |
| Average Indigestion Syndrome Score | -0.01 ± 1.138 | 0.09 ± 0.865 | -0.03 ± 0.811 | -0.14 ± 0.820 | -0.31 ± 1.046 | -0.54 ± 1.007 |
| Average Constipation Syndrome Score | -0.03 ± 1.045 | -0.15 ± 0.989 | 0.32 ± 1.370 | -0.02 ± 0.934 | -0.32 ± 1.215 | -0.37 ± 0.772 |
| Average Abdominal Pain Syndrome Score | -0.05 ± 1.074 | 0.06 ± 0.712 | -0.02 ± 1.000 | -0.06 ± 0.629 | -0.08 ± 0.885 | -0.25 ± 0.904 |
| Average Reflux Syndrome Score | -0.09 ± 1.208 | -0.13 ± 0.619 | -0.20 ± 1.332 | -0.26 ± 0.664 | -0.16 ± 0.762 | -0.43 ± 0.847 |
| Average Total Score | 0.01 ± 0.830 | 0.02 ± 0.668 | 0.07 ± 0.802 | -0.11 ± 0.433 | -0.23 ± 0.690 | -0.28 ± 0.695 |
Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Number of participants with Mean Worst Daily Itch Score of \<4 at Week 16 is presented.
| Participants | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Number of Participants With Mean Worst Daily Itch Score of <4 at Week 16 | 21 | 13 | 14 | 18 | 18 | 14 |
Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.
| Participants | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Number of Participants With Improvement of >= 30 Percent (%) in the Mean Worst Daily Itch Score at Week 16 From Baseline | 17 | 9 | 15 | 14 | 15 | 14 |
Participants were required to score the severity of their itching using a 0-10 NRS where 0 represents no itching and 10 indicates the worst imaginable itching. The Worst Daily Itch Score is the most severe (highest) NRS recorded on a given day. Mean Worst Daily Itch score was calculated as the average of the worst daily itch scores provided in the 7 days prior to the Week 16 visit. Baseline is the most recent assessment completed by the participant prior to randomization. Number of participants with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.
| Participants | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Number of Participants With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline | 14 | 6 | 12 | 9 | 13 | 12 |
Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Percentage of responder days with Worst Daily Itch Score of \<4 is presented.
| Percentage of days | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Responder Days With Worst Daily Itch Score of <4 | 40.32 (28.79 to 51.86) | 58.53 (41.23 to 75.83) | 51.38 (36.95 to 65.81) | 58.76 (45.45 to 72.08) | 65.80 (51.37 to 80.23) | 53.58 (38.83 to 68.34) |
Percentage of Responder Days with Worst Daily Itch score was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>= 30% in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented..
| Percentage of days | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Responder Days With Improvement of >= 30% in the Mean Worst Daily Itch Score at Week 16 From Baseline | 38.46 (27.30 to 49.61) | 53.44 (36.71 to 70.18) | 45.43 (31.47 to 59.39) | 50.23 (37.35 to 63.12) | 60.29 (46.33 to 74.25) | 60.03 (45.76 to 74.31) |
Percentage of Responder Days with Worst Daily Itch was calculated as: (number of days response from Visit 3+1 to Visit 6-1 divided by number of days from Visit 3+1 to Visit 6-1 with worst daily itch scores available) times 100. Days for which no worst daily itch score was available did not contribute to either the numerator or the denominator. Analysis was performed using ANCOVA model including treatment group. Baseline is the most recent assessment completed by the participant prior to randomization. Percentage of responder days with improvement of \>=2 in the Mean Worst Daily Itch Score at Week 16 from Baseline is presented.
| Percentage of days | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Percentage of Responder Days With Improvement of >=2 in the Mean Worst Daily Itch Score at Week 16 From Baseline | 31.56 (19.96 to 43.16) | 37.71 (20.31 to 55.11) | 38.82 (24.31 to 53.33) | 40.69 (27.29 to 54.08) | 51.49 (36.98 to 66.00) | 58.60 (43.76 to 73.43) |
Mean Daily Sleep Score is defined as the average of the daily sleep scores provided in the 7 days prior to the relevant visit. Participants sleep quality was recorded in an electronic diary each morning using a 0-10 NRS in which 0: good sleep to 10:worst possible sleep. Higher score indicates worse possible sleep. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA including treatment group and Baseline.
| Scores on a scale | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in the Mean Daily Sleep Score at Week 16 | -1.39 (-2.06 to -0.72) | -1.66 (-2.64 to -0.67) | -1.87 (-2.75 to -0.99) | -1.85 (-2.69 to -1.01) | -2.35 (-3.19 to -1.50) | -1.69 (-2.57 to -0.81) |
Mean Daily Fatigue Score is defined as the average of the daily fatigue scores provided in the 7 days prior to the relevant visit. Participants fatigue level was recorded in an electronic diary each evening using a 0-10 NRS in which 0: no fatigue to 10:worst possible fatigue. Higher score indicates worse possible fatigue. Baseline is the average of the scores in the 7 days prior to the Week 4 (V3) visit. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Analysis was performed using ANCOVA model including treatment group and Baseline.
| Scores on a scale | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Change From Baseline in the Mean Daily Fatigue Score at Week 16 | -0.79 (-1.39 to -0.18) | -1.18 (-2.08 to -0.27) | -1.19 (-2.00 to -0.37) | -1.04 (-1.81 to -0.28) | -1.20 (-1.97 to -0.44) | -1.07 (-1.86 to -0.29) |
The 5-D itch scale had been developed as a brief, single page, instrument for the multidimensional quantification of itch that is sensitive to change over time. It has data to support its validity in a population of participants with pruritus and covers five dimensions of itch experienced by participants: duration, degree, direction, disability and distribution. Each domain was scored on a 5-point scale, ranging from 1 (Not present/resolved/never) to 5 (unbearable/getting worse/always), higher scores indicates worst itching. The scores of each of five domains were achieved separately and then summed together to obtain a total 5-D score. A total 5-D scores potentially ranged between 5 (no pruritus) and 25 (most severe pruritus) where higher score indicates worse possible itching. Baseline is assessment performed at Week 4 (V3) which is conducted prior to first dosing of randomized medication that evening. Change from Baseline was calculated as post-Baseline value minus Baseline value.
| Scores on a scale | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Duration | -0.8 (-1.1 to -0.4) | -0.9 (-1.3 to -0.4) | -0.4 (-0.8 to 0.0) | -1.2 (-1.6 to -0.8) | -0.6 (-1.0 to -0.2) | -0.7 (-1.1 to -0.3) |
| Degree | -0.7 (-1.0 to -0.4) | -0.9 (-1.4 to -0.5) | -0.7 (-1.1 to -0.3) | -0.7 (-1.2 to -0.3) | -0.9 (-1.3 to -0.5) | -0.8 (-1.2 to -0.4) |
| Direction | -0.7 (-1.1 to -0.3) | -0.7 (-1.3 to -0.1) | -0.7 (-1.2 to -0.2) | -0.9 (-1.4 to -0.4) | -1.1 (-1.6 to -0.6) | -0.7 (-1.2 to -0.2) |
| Disability | -0.4 (-0.7 to 0.0) | -0.8 (-1.4 to -0.2) | -0.5 (-1.0 to 0.0) | -0.7 (-1.2 to -0.2) | -0.7 (-1.2 to -0.2) | -0.7 (-1.2 to -0.1) |
| Distribution | -0.4 (-0.7 to -0.1) | -0.7 (-1.2 to -0.2) | -0.7 (-1.1 to -0.3) | -0.9 (-1.3 to -0.5) | -0.7 (-1.2 to -0.3) | -0.6 (-1.0 to -0.2) |
| 5-D Itch Total Score | -3.0 (-4.2 to -1.7) | -4.0 (-5.9 to -2.0) | -3.0 (-4.7 to -1.3) | -4.4 (-6.0 to -2.7) | -3.8 (-5.4 to -2.2) | -3.5 (-5.2 to -1.8) |
Blood samples were collected for evaluating total bile acid concentration as a biomarker of PBC. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Micromoles per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Serum Total Bile Acid Concentration | -4.274 ± 20.0163 | -0.469 ± 6.5466 | -3.878 ± 40.1857 | -1.114 ± 6.9359 | -2.133 ± 8.9308 | 7.379 ± 38.8282 |
Blood samples were collected for evaluating C4 concentration as a marker of bile acid synthesis. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 or Visit 1, excluding unscheduled visits. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Micrograms per Liter | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline at Week 16 in Serum 7-alpha Hydroxy-4-cholesten-3-one (C4) | 4.746 ± 11.5644 | 10.703 ± 24.6045 | 11.452 ± 16.6371 | 29.488 ± 38.7584 | 58.674 ± 59.4833 | 40.629 ± 36.2769 |
Blood samples were collected for measurement of plasma GSK2330672 concentration.
| Picograms per milliliter | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|
| Week 4, Between 1 and 3 hours post-dose, n=6, 2, 7, 0, 4 | 5.00 ± NA | 5.00 ± NA | 32.71 ± 73.325 | — | 5.00 ± NA |
| Week 8, Between 1 and 3 hours post-dose, n=16, 21, 20, 22, 17 | 358.04 ± 665.685 | 958.81 ± 1563.265 | 2327.58 ± 3737.965 | 453.45 ± 967.424 | 2908.06 ± 5106.895 |
| Week 8, Between 5 and 8 hours post-dose, n=14, 17, 18, 21, 16 | 300.04 ± 356.268 | 820.87 ± 1143.023 | 2234.28 ± 3420.442 | 339.74 ± 357.914 | 1990.89 ± 4061.978 |
| Week 12, Between 1 and 3 hours post-dose, n=14, 19, 17, 20, 14 | 447.88 ± 1160.518 | 1594.16 ± 3133.370 | 2060.51 ± 2888.033 | 419.47 ± 774.321 | 3531.36 ± 6296.828 |
| Week 12, Between 5 and 8 hours post-dose, n=14, 16, 17, 20, 13 | 341.39 ± 638.359 | 1084.00 ± 1353.089 | 2569.00 ± 3727.883 | 303.83 ± 300.716 | 2197.16 ± 3604.704 |
| Week 16, Between 1 and 3 hours post-dose, n=3, 5, 4, 2, 5 | 394.00 ± 162.151 | 864.26 ± 1045.467 | 3328.50 ± 3185.646 | 338.50 ± 236.881 | 703.60 ± 756.010 |
| Week 16, Between 5 and 8 hours post-dose, n=3, 3, 4, 2, 5 | 296.33 ± 118.154 | 578.00 ± 651.263 | 1940.50 ± 1128.203 | 364.50 ± 217.082 | 869.40 ± 1148.331 |
Participants were required to score severity of their itching each morning and evening using a 0-10 NRS where 0(no itching) and 10(worst imaginable itching). The worst of these 2 scores was Worst Daily Itch Score. For each week, mean Worst Daily Itch Score was calculated to form Mean Worst Daily Itch Score. The Monthly Itch Score was defined as worst weekly score (e.g., Mean Worst Daily Itch Score) for that month. The monthly itch score ranges from 0 to 10, higher score indicates worst imaginable itching. Baseline is average of scores in the 7 days prior to Week 4 (Visit 3 \[V3\]). Change from Baseline was calculated as post-Baseline value minus Baseline value. Mean change from Baseline in monthly itch score over 12 week treatment period is presented. Analysis was performed on change in Monthly Itch Scores over 12 week treatment period using Mixed model repeated measures (MMRM) with Baseline itch, treatment group, visit and a treatment group\*visit interaction as covariates in the model.
| Scores on a scale | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Monthly Itch Score | -0.46 (-1.01 to 0.08) | -1.17 (-1.99 to -0.35) | -1.08 (-1.77 to -0.39) | -1.36 (-2.03 to -0.69) | -1.63 (-2.32 to -0.93) | -1.41 (-2.13 to -0.7) |
Blood samples were collected for evaluation of total bile acid concentration as a biomarker of PBC. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Ratio to Baseline was defined as the geometric mean of post-Baseline visit value divided by the geometric mean of Baseline value. Values were log-transformed and mean change from Baseline on the log-scale was calculated over the 12 week treatment period. Analysis was performed on change in total serum bile acid concentration on the log-scale over the 12 week treatment period using Mixed model repeated measures (MMRM) with log-transformed Baseline total serum bile acid, visit, treatment group, a log-transformed Baseline total serum bile acid\*visit interaction, and a treatment group\*visit interaction used as covariates in the model. Afterwards, values were back-transformed to the original scale. Ratios of geometric means are presented.
| Ratio | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Ratio to Baseline in Total Serum Bile Acid Concentration | 1.01 (0.801 to 1.273) | 0.977 (0.688 to 1.386) | 1.182 (0.874 to 1.6) | 0.918 (0.687 to 1.226) | 0.697 (0.519 to 0.938) | 0.833 (0.616 to 1.127) |
Blood samples were collected for evaluation of C4 concentration as a marker of bile acid synthesis. Baseline is the assessment performed at Week 4 (V3), or if missing then Visit 2 (Day 1) or Visit 1 (Screening), excluding unscheduled visits. Ratio to Baseline was defined as the geometric mean of post-Baseline visit value divided by the geometric mean of Baseline value. Values were log-transformed and mean change from Baseline on the log-scale was calculated over the 12 week treatment period. Analysis was performed on change in C4 on the log-scale over the 12 week treatment period using Mixed model repeated measures (MMRM) with log-transformed Baseline C4, visit, treatment group, a log-transformed Baseline C4\*visit interaction, and a treatment group\*visit interaction used as covariates in the model. Afterwards, values were back-transformed to the original scale. Ratios of geometric means are presented.
| Ratio | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID |
|---|---|---|---|---|---|---|
| Ratio to Baseline in Serum 7-alpha-hydroxy-4-cholesten-3-one (C4) Concentration | 1.158 (0.937 to 1.431) | 1.579 (1.151 to 2.166) | 2.374 (1.812 to 3.109) | 2.846 (2.192 to 3.694) | 3.622 (2.753 to 4.764) | 3.127 (2.385 to 4.101) |
Collected over Non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 12 weeks during Main study period; up to 4 weeks during Final study period and up to 4 weeks during Follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Main Study Period | 0/36 (0%) | 0/36 (0%) | 17/36 (47.2%) |
| GSK2330672 20 mg QD - Main Study Period | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| GSK2330672 90 mg QD - Main Study Period | 0/23 (0%) | 1/23 (4.3%) | 19/23 (82.6%) |
| GSK2330672 180 mg QD - Main Study Period | 0/27 (0%) | 0/27 (0%) | 24/27 (88.9%) |
| GSK2330672 40 mg BID - Main Study Period | 0/23 (0%) | 0/23 (0%) | 16/23 (69.6%) |
| GSK2330672 90 mg BID - Main Study Period | 0/22 (0%) | 0/22 (0%) | 18/22 (81.8%) |
| Placebo - Final Study Period | 0/35 (0%) | 0/35 (0%) | 2/35 (5.7%) |
| GSK2330672 20 mg QD - Final Study Period | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| GSK2330672 90 mg QD - Final Study Period | 0/19 (0%) | 0/19 (0%) | 8/19 (42.1%) |
| GSK2330672 180 mg QD - Final Study Period | 0/19 (0%) | 0/19 (0%) | 2/19 (10.5%) |
| GSK2330672 40 mg BID - Final Study Period | 0/21 (0%) | 0/21 (0%) | 2/21 (9.5%) |
| GSK2330672 90 mg BID - Final Study Period | 0/17 (0%) | 0/17 (0%) | 2/17 (11.8%) |
| Placebo - Follow-up | 0/35 (0%) | 0/35 (0%) | 0/35 (0%) |
| GSK2330672 20 mg QD - Follow-up | 0/16 (0%) | 1/16 (6.3%) | 0/16 (0%) |
| GSK2330672 90 mg QD - Follow-up | 0/23 (0%) | 0/23 (0%) | 0/23 (0%) |
| GSK2330672 180 mg QD - Follow-up | 0/27 (0%) | 1/27 (3.7%) | 0/27 (0%) |
| GSK2330672 40 mg BID - Follow-up | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| GSK2330672 90 mg BID - Follow-up | 0/22 (0%) | 0/22 (0%) | 0/22 (0%) |
| Event | Placebo - Main Study Period | GSK2330672 20 mg QD - Main Study Period | GSK2330672 90 mg QD - Main Study Period | GSK2330672 180 mg QD - Main Study Period | GSK2330672 40 mg BID - Main Study Period | GSK2330672 90 mg BID - Main Study Period | Placebo - Final Study Period | GSK2330672 20 mg QD - Final Study Period | GSK2330672 90 mg QD - Final Study Period | GSK2330672 180 mg QD - Final Study Period | GSK2330672 40 mg BID - Final Study Period | GSK2330672 90 mg BID - Final Study Period | Placebo - Follow-up | GSK2330672 20 mg QD - Follow-up | GSK2330672 90 mg QD - Follow-up | GSK2330672 180 mg QD - Follow-up | GSK2330672 40 mg BID - Follow-up | GSK2330672 90 mg BID - Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 0/36 | 0/16 | 0/23 | 0/27 | 0/23 | 0/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 1/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/36 | 0/16 | 1/23 | 0/27 | 0/23 | 0/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| ConstipationGastrointestinal disorders | 0/36 | 0/16 | 0/23 | 0/27 | 0/23 | 0/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 1/27 | 0/22 | 0/22 |
| Event | Placebo - Main Study Period | GSK2330672 20 mg QD - Main Study Period | GSK2330672 90 mg QD - Main Study Period | GSK2330672 180 mg QD - Main Study Period | GSK2330672 40 mg BID - Main Study Period | GSK2330672 90 mg BID - Main Study Period | Placebo - Final Study Period | GSK2330672 20 mg QD - Final Study Period | GSK2330672 90 mg QD - Final Study Period | GSK2330672 180 mg QD - Final Study Period | GSK2330672 40 mg BID - Final Study Period | GSK2330672 90 mg BID - Final Study Period | Placebo - Follow-up | GSK2330672 20 mg QD - Follow-up | GSK2330672 90 mg QD - Follow-up | GSK2330672 180 mg QD - Follow-up | GSK2330672 40 mg BID - Follow-up | GSK2330672 90 mg BID - Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/36 | 6/16 | 15/23 | 18/27 | 12/23 | 15/22 | 1/35 | 1/16 | 0/19 | 0/19 | 1/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| Abdominal painGastrointestinal disorders | 3/36 | 3/16 | 4/23 | 8/27 | 2/23 | 4/22 | 0/35 | 1/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| ConstipationGastrointestinal disorders | 0/36 | 0/16 | 4/23 | 0/27 | 0/23 | 0/22 | 0/35 | 0/16 | 1/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| NauseaGastrointestinal disorders | 1/36 | 1/16 | 1/23 | 4/27 | 0/23 | 2/22 | 1/35 | 1/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| NasopharyngitisInfections and infestations | 1/36 | 1/16 | 1/23 | 1/27 | 0/23 | 3/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| HeadacheNervous system disorders | 0/36 | 1/16 | 3/23 | 2/27 | 1/23 | 1/22 | 0/35 | 0/16 | 1/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| Abdominal pain upperGastrointestinal disorders | 0/36 | 2/16 | 0/23 | 2/27 | 1/23 | 0/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| AstheniaGeneral disorders | 0/36 | 2/16 | 0/23 | 1/27 | 1/23 | 0/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| Dry eyeEye disorders | 0/36 | 2/16 | 1/23 | 0/27 | 0/23 | 0/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
| Dry mouthGastrointestinal disorders | 0/36 | 2/16 | 1/23 | 0/27 | 1/23 | 0/22 | 0/35 | 0/16 | 0/19 | 0/19 | 0/21 | 0/17 | 0/35 | 0/16 | 0/23 | 0/27 | 0/22 | 0/22 |
Baseline characteristics is presented for Safety Population which consisted of all randomized participants who took at least one dose of randomized study treatment.
| Age, Continuous(Years) | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.4 ± 11.06 | 58.5 ± 7.35 | 52.5 ± 12.32 | 58.9 ± 11.10 | 55.6 ± 11.23 | 56.2 ± 11.32 | 55.8 ± 11.04 |
| Sex: Female, Male(Participants) | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID | Total |
|---|---|---|---|---|---|---|---|
| Female | 34 | 16 | 21 | 25 | 22 | 20 | 138 |
| Male | 2 | 0 | 2 | 2 | 1 | 2 | 9 |
| Race/Ethnicity, Customized(Participants) | Placebo | GSK2330672 20 mg QD | GSK2330672 90 mg QD | GSK2330672 180 mg QD | GSK2330672 40 mg BID | GSK2330672 90 mg BID | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaskan Native | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian - Japanese Heritage | 8 | 6 | 6 | 7 | 4 | 7 | 38 |
| White - White/Caucasian/European Heritage | 26 | 10 | 17 | 19 | 16 | 15 | 103 |
| Multiple | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Unknown | 2 | 0 | 0 | 0 | 2 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2017 to primary completion in Apr 2020, 39 months.
Results were first posted in May 2021, 1 year after primary completion.
Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 39 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linerixibat